Biden Administration's Threat to Use 'March-In Rights' on Prescription Drugs
The Biden administration is threatening to use 'march-in rights' to increase government control over prescription drugs, which could impact innovation in the pharmaceutical industry. Critics argue that this move is more about expanding government power than helping consumers with affordable medical expenses.
Key Points
- Biden administration considering using 'march-in rights' to control prescription drug prices
- Critics view move as a way to expand government power rather than help consumers
- Bipartisan Bayh-Dole Act protects patent holders from 'march-in' actions
Cons
- Potential impact on innovation in pharmaceutical industry
- Critics argue it's more about expanding government power than helping consumers